Melinta Therapeutics, Inc. /New/☆Watch⊞Compare

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Melinta Therapeutics, Inc. /New/ is one of 1613 Pharmaceuticals companies tracked from NEW HAVEN. By capital raised it ranks among the largest (ahead of 98% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Round size and date are reported; the stage label is inferred from round size (latest is Series D+ — a $100M–$400M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Raised more than 98% of sector peers (real $). Modeled value above 98% of peers (estimate).

A tighter cohort than the sector chart above — only companies at the same stage (Series D+) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #4 of 11.

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

1. Series C$46.0M2009-05-13
   • First recorded raise — entered as Series C.
   • 15 investors on this round.
2. Series B$25.5M2009-05-13
   • Filed alongside the prior round (same month) — likely a tranche or amendment.
   • Round 1.8× smaller than the prior — bridge or down round.
   • 15 investors on this round.
3. Series C$5.0M2011-08-05
   • Raised again after 27 mo — slower than the ~13 mo sector norm.
   • Round 5.1× smaller than the prior — bridge or down round.
   • 16 investors on this round.
4. Series C$25.1M2012-10-24
   • Raised 15 mo later, in step with the ~13 mo sector norm.
   • Round 5.0× larger than the prior — scaling up.
   • 13 investors on this round.
5. Series D+$132.9M2017-11-03
   • Raised again after 60 mo — slower than the ~13 mo sector norm.
   • Round 5.3× larger than the prior — scaling up.
   • Switched to Rule 506(b) (was Rule 06).
   • 39 investors on this round.
6. Series D+$137.8M2018-01-05
   • Came back fast: 2 mo vs the ~13 mo sector norm.
   • Round roughly the size of the prior one.
   • 9 investors on this round.

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

Melinta Therapeutics, Inc. /New/ is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

See where Melinta Therapeutics, Inc. /New/ sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

If you work at Melinta Therapeutics, Inc. /New/, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.